AstraZeneca, in collaboration with Vall d’Hebron and Tucuvi, have presented AZerca, a program that enables personalized monitoring of patients with congestive heart failure through artificial intelligence and conversational technology. This follow-up strategy is expected to enable healthcare professionals to achieve better control of patients, decreasing the need for hospital care, which will result in resource optimization and improved quality of life for patients.

Through the virtual voice assistant called LOLA, patients are contacted by telephone to collect information about their health status at a frequency determined by the clinical team. The data collected are automatically analyzed and structured in the Tucuvi Health Manager platform to be subsequently reviewed by the specialized nursing team prioritizing preconfigured alerts that allow focusing attention on those patients with a higher risk of decompensation or changes in their usual clinic.

The program will involve around 90 patients from the Heart Failure Unit of the Cardiology Department of the Vall d’Hebron University Hospital in Barcelona and the follow-up will last between 6 and 12 months. The objective is to evaluate the feasibility of implementing the tool in the Cardiology Department of the Vall d’Hebron University Hospital and to analyze the improvements that it could bring to the unit. LOLA is a voice-based virtual medical assistant based on AI that allows continuous and personal monitoring of each patient through autonomous telephone calls. With more than 60,000 patients served, LOLA helps hospitals ensure that patients receive continuous, high-quality care while maintaining an essential human touch.

Article written by World Nation News Desk/ Image by Vall d’Hebron



World Nation News